Media headlines about Neurocrine Biosciences (NASDAQ:NBIX) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.3018803753467 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Neurocrine Biosciences, Inc. (NBIX) Given “Buy” Rating at Needham & Company LLC (americanbankingnews.com)
- Neurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the … – PR Newswire (press release) (prnewswire.com)
- Neurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual Psych Congress (finance.yahoo.com)
- Zacks: Analysts Anticipate Neurocrine Biosciences, Inc. (NBIX) Will Announce Earnings of -$0.50 Per Share (americanbankingnews.com)
- 10 Top Penny Stocks to Watch in September 2017 (moneymorning.com)
A number of analysts have recently weighed in on the company. Cowen and Company reissued an “outperform” rating and set a $65.00 price objective (up previously from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. Needham & Company LLC reissued a “buy” rating and set a $58.00 price objective (down previously from $62.00) on shares of Neurocrine Biosciences in a research note on Wednesday, May 24th. J P Morgan Chase & Co set a $57.00 price objective on Neurocrine Biosciences and gave the company a “buy” rating in a research note on Wednesday, May 24th. Leerink Swann dropped their price objective on Neurocrine Biosciences from $68.00 to $66.00 and set an “outperform” rating for the company in a research note on Thursday, May 25th. Finally, BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Neurocrine Biosciences has a consensus rating of “Buy” and a consensus price target of $68.25.
Neurocrine Biosciences (NASDAQ NBIX) opened at 56.80 on Thursday. The company’s market capitalization is $5.01 billion. Neurocrine Biosciences has a one year low of $37.35 and a one year high of $60.00. The stock’s 50 day moving average price is $54.39 and its 200 day moving average price is $49.17.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.01). The firm had revenue of $6.34 million during the quarter, compared to analysts’ expectations of $0.61 million. During the same period last year, the firm posted ($0.46) earnings per share. Equities analysts anticipate that Neurocrine Biosciences will post ($2.45) EPS for the current fiscal year.
In related news, insider Christopher Flint Obrien sold 8,734 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $50.00, for a total transaction of $436,700.00. Following the transaction, the insider now directly owns 57,707 shares of the company’s stock, valued at approximately $2,885,350. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Haig P. Bozigian sold 22,500 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $50.00, for a total value of $1,125,000.00. Following the transaction, the insider now directly owns 154,601 shares in the company, valued at $7,730,050. The disclosure for this sale can be found here. Insiders have sold a total of 125,655 shares of company stock worth $7,018,148 over the last ninety days. 4.80% of the stock is currently owned by corporate insiders.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.